rethinklymphoma.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Disallow: /wp-admin/ Sitemap: https://www.rethinklymphoma.com/sitemap.xml | ||
Meta Tags
| Title | The Unmet Need of Patients with Aggressive |
| Description | PATIENTS WITH AGGRESSIVE DISEASE NEED MORE Patients with R/R large B cell lymphoma face poor outcomes with the current standard of care. Learn more about the gap in treatment of relapsed |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 165.89.235.63 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
rethinklymphoma.com Valuation
|
US$306,376
Last updated: 2022-12-25 07:57:12
rethinklymphoma.com has Semrush global rank of 34,546,812. rethinklymphoma.com has an estimated worth of US$ 306,376, based on its estimated Ads revenue. rethinklymphoma.com receives approximately 35,352 unique visitors each day. Its web server is located in United States, with IP address 165.89.235.63. According to SiteAdvisor, rethinklymphoma.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$306,376 |
| Daily Ads Revenue | US$283 |
| Monthly Ads Revenue | US$8,485 |
| Yearly Ads Revenue | US$101,811 |
| Daily Unique Visitors | 2,357 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| rethinklymphoma.com. | A | 598 | IP: 165.89.235.63 |
| rethinklymphoma.com. | NS | 600 | NS Record: ns4.bms.com. |
| rethinklymphoma.com. | NS | 600 | NS Record: ns2.bms.com. |
| rethinklymphoma.com. | NS | 600 | NS Record: FRA-EXDNS-1.net.bms.com. |
| rethinklymphoma.com. | NS | 600 | NS Record: ns1.bms.com. |
| rethinklymphoma.com. | NS | 600 | NS Record: ns3.bms.com. |
| rethinklymphoma.com. | TXT | 600 | TXT Record: 8w2n99q9vh04qf9s5wz7k87fzvw5l3w4 |
HtmlToTextCheckTime:2022-12-25 07:57:12
| PATIENTS WITH AGGRESSIVE DISEASE NEED MORE OPTIONS In large B-cell lymphoma, patients who are primary refractory or relapse (≤12 months) face poor outcomes with current standard of care. 1 DISCOVER MORE ABOUT THIS UNMET NEED UNMET NEED SLIDE DECK Despite the curative intent of current treatment options, rates of relapse in DLBCL are high and survival rates remain poor 1 An aggressive disease in newly diagnosed patients, DLBCL is the most common subtype of non-Hodgkin lymphoma and accounts for up to 30% of cases in the United States. 2-4 As disease progresses after second line and later lines of therapy, treatment options narrow. FIRST LINE 30 % -40 % of patients are refractory to or relapse after 1L chemotherapy-containing combination regimens and progress to second-line therapy 4 * SECOND LINE 20 % of transplant-eligible patients are expected to have a 3-year PFS Salvage chemotherapy followed by HDT and ASCT has been the standard of care for more than 20 years for eligible patients |
HTTP Headers
HTTP/1.0 301 Moved Permanently Location: http://www.rethinklymphoma.com/ Server: BigIP Connection: Keep-Alive Content-Length: 0 HTTP/1.1 301 Moved Permanently Server: CloudFront Date: Wed, 19 Oct 2022 08:42:17 GMT Content-Type: text/html Content-Length: 167 Connection: close Location: https://www.rethinklymphoma.com/ X-Cache: Redirect from cloudfront Via: 1.1 3f25be8570bf62f8d4607f79984fccec.cloudfront.net (CloudFront) X-Amz-Cf-Pop: ARN56-P1 X-Amz-Cf-Id: jAzIKD7loizwhKXaMMXDkMG03ptVhKBk50vtfYNGjsCt11mbSatlHA== HTTP/2 301 content-type: text/html; charset=iso-8859-1 location: https://www.rethinklymphoma.com/lbcl date: Wed, 19 Oct 2022 08:42:17 GMT server: Apache x-cache: Miss from cloudfront via: 1.1 419f3eb3d74bedebbef6fc91b3f54a36.cloudfront.net (CloudFront) x-amz-cf-pop: ARN56-P1 x-amz-cf-id: TVNy4GthZuv4kL9RYHFnMno72XiQ_8hk2WaP4WSl2PkizxsvdUVD-Q== HTTP/2 200 content-type: text/html;charset=utf-8 date: Wed, 19 Oct 2022 08:42:17 GMT server: Apache x-content-type-options: nosniff accept-ranges: bytes x-dispatcher: dispatcher2useast1 x-dispatcher-number: 2 x-vhost: publish x-frame-options: SAMEORIGIN strict-transport-security: max-age=63072000; includeSubDomains; preload content-security-policy: default-src https: blob: 'unsafe-inline' 'unsafe-eval'; media-src https: blob:; font-src https: data:;img-src https: data:; cache-control: max-age=600,s-maxage=600 vary: Accept-Encoding,User-Agent x-cache: Miss from cloudfront via: 1.1 419f3eb3d74bedebbef6fc91b3f54a36.cloudfront.net (CloudFront) x-amz-cf-pop: ARN56-P1 x-amz-cf-id: MgDVM1cwZ9u_bTnp3YiHv9tFdaJDnBFa2zYgV8LUqgl8OXC9xf1byg== |
rethinklymphoma.com Whois Information
Domain Name: RETHINKLYMPHOMA.COM Registry Domain ID: 2644286217_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2022-08-15T15:59:07Z Creation Date: 2021-09-28T21:59:26Z Registry Expiry Date: 2023-09-28T21:59:26Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS1.BMS.COM Name Server: NS2.BMS.COM Name Server: NS3.BMS.COM Name Server: NS4.BMS.COM DNSSEC: unsigned >>> Last update of whois database: 2022-10-19T08:39:07Z <<< |